XW0L3HA
Introduction Coronary Artery, Three Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, One Balloon, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | L Coronary Artery, Three Arteries |
| Approach | 3 Percutaneous |
| Device | H Paclitaxel-Coated Balloon Technology, One Balloon |
| Qualifier | A New Technology Group 10 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Coronary Artery, Three Arteries
Coding to three coronary arteries under New Technology Introduction captures cases where a novel therapeutic agent, such as an engineered infusion for microvascular disease or a specialized therapeutic substance, is delivered into three distinct coronary vessels during a single encounter. The three-artery designation matters because coronary anatomy is rarely uniform: the left anterior descending, circumflex, and right coronary arteries each supply separate myocardial territories, so treating three of them reflects broader disease distribution than a single-vessel approach. Documentation must specify which three vessels received the substance and confirm the delivery method, since New Technology codes track emerging agents whose safety and efficacy data are still accumulating. Accurate vessel-count coding also supports post-market surveillance, letting registries correlate outcomes with the extent of coronary involvement treated in a given session.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Paclitaxel-Coated Balloon Technology, One Balloon
This value specifies use of a paclitaxel drug-coated balloon during an endovascular procedure where exactly one balloon was used to deliver the antiproliferative drug to the vessel wall while dilating a stenosis. The balloon count distinguishes it from the otherwise identical two-, three-, and four-or-more-balloon values, which document greater procedural extent or multiple treated lesions rather than a different device or drug.
Qualifier: New Technology Group 10
New Technology Group 10 flags a procedure as part of the 2023 batch of add-on codes recognized under the New Technology section. The value itself carries no information about the device or drug involved; that comes from the table, body part, and approach values alongside it. Coders should not confuse it with Group 9 or Group 11, which cover the cohorts approved in the years immediately before and after.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.